Group 1 - The core point of the article is that Sinovac Biotech Ltd. has received approval from the Nasdaq Hearing Committee to maintain its listing status on the Nasdaq Global Market, provided it submits its financial reports by May 11, 2026 [1][3] - The company must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by the specified deadline [4][5] - Sinovac has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to expedite the audit and reporting process [1][4] Group 2 - Sinovac's delisting crisis began over two months ago when it received a delisting notice from Nasdaq due to its failure to submit the required annual report on time [4][6] - The company reported a significant increase in revenue and net profit in 2021, with total revenue reaching 135.487 billion yuan, a year-on-year increase of 3694.36%, and net profit of 59.212 billion yuan, a year-on-year increase of 7571.97% [6][7] - However, the demand for COVID-19 vaccines has sharply declined, leading to a significant drop in revenue and net profit in 2022 and 2023, with revenue decreasing by 92.30% and 69.97%, and net profit decreasing by 98.66% and 187.75% respectively [7] Group 3 - Sinovac has a diverse product pipeline, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine, with recent approvals for new products such as the 23-valent pneumococcal polysaccharide vaccine [7] - The international market is becoming a new growth area for Sinovac, with recent successes in obtaining WHO pre-certification for certain vaccines and winning exclusive bids for influenza vaccine orders in Chile [7] - Internal governance issues remain unresolved, with ongoing conflicts between management and significant shareholders affecting the company's stability and operations [7]
科兴控股获准维持美股上市地位 两份财报还剩约110天发布窗口期